Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

Science. 1998 Jan 23;279(5350):563-6. doi: 10.1126/science.279.5350.563.

Abstract

Insulin-like growth factor-I (IGF-I) is a mitogen for prostate epithelial cells. To investigate associations between plasma IGF levels and prostate cancer risk, a nested case-control study within the Physicians' Health Study was conducted on prospectively collected plasma from 152 cases and 152 controls. A strong positive association was observed between IGF-I levels and prostate cancer risk. Men in the highest quartile of IGF-I levels had a relative risk of 4.3 (95 percent confidence interval 1.8 to 10.6) compared with men in the lowest quartile. This association was independent of baseline prostate-specific antigen levels. Identification of plasma IGF-I as a predictor of prostate cancer risk may have implications for risk reduction and treatment.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Analysis of Variance
  • Case-Control Studies
  • Confidence Intervals
  • Disease Susceptibility
  • Humans
  • Insulin-Like Growth Factor Binding Protein 3 / blood
  • Insulin-Like Growth Factor I / analysis*
  • Insulin-Like Growth Factor II / analysis
  • Male
  • Middle Aged
  • Odds Ratio
  • Prospective Studies
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / etiology*
  • Reference Values
  • Regression Analysis
  • Risk
  • Risk Factors

Substances

  • Insulin-Like Growth Factor Binding Protein 3
  • Insulin-Like Growth Factor I
  • Insulin-Like Growth Factor II
  • Prostate-Specific Antigen